ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio5.84
Quick Ratio5.24
Price-To-Earnings
Trailing P/E Ratio180.88
Forward P/E Ratio125.46
P/E Growth4.7
Sales & Book Value
Annual Sales$593.75 million
Price / Sales32.90
Cash Flow$2.7537 per share
Price / Cash159.46
Book Value$15.57 per share
Price / Book28.20
Profitability
EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins18.89%
Return on Equity17.58%
Return on Assets15.37%
Miscellaneous
Employees1,143
Outstanding Shares44,480,000
ABIOMED (NASDAQ:ABMD) Frequently Asked Questions
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
How were ABIOMED's earnings last quarter?
ABIOMED, Inc. (NASDAQ:ABMD) released its quarterly earnings results on Thursday, May, 3rd. The medical equipment provider reported $0.80 EPS for the quarter, beating the Zacks' consensus estimate of $0.64 by $0.16. The medical equipment provider had revenue of $174.44 million for the quarter, compared to analyst estimates of $164.30 million. ABIOMED had a net margin of 18.89% and a return on equity of 17.58%. The company's revenue for the quarter was up 39.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.33 earnings per share. View ABIOMED's Earnings History.
When is ABIOMED's next earnings date?
What price target have analysts set for ABMD?
8 Wall Street analysts have issued 12 month price objectives for ABIOMED's stock. Their predictions range from $280.00 to $460.00. On average, they expect ABIOMED's stock price to reach $346.00 in the next twelve months. View Analyst Ratings for ABIOMED.
Who are some of ABIOMED's key competitors?
Some companies that are related to ABIOMED include Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE) and Cantel Medical (CMD).
Who are ABIOMED's key executives?
ABIOMED's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, Chief Exec. Officer and Pres (Age 51)
- Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
- Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
- Mr. Todd A. Trapp, CFO & VP (Age 47)
Has ABIOMED been receiving favorable news coverage?
News coverage about ABMD stock has trended positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ABIOMED earned a news impact score of 0.48 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 45.56 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are ABIOMED's major shareholders?
ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.35%), Baillie Gifford & Co. (4.62%), Palo Alto Investors LP (3.04%), Winslow Capital Management LLC (1.77%), American Century Companies Inc. (1.75%) and Franklin Resources Inc. (1.41%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.
Which institutional investors are selling ABIOMED stock?
ABMD stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Millennium Management LLC, American Century Companies Inc., Wells Fargo & Company MN, Sei Investments Co., Scout Investments Inc., Blair William & Co. IL and OppenheimerFunds Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Paul Thomas and William J Bolt. View Insider Buying and Selling for ABIOMED.
Which institutional investors are buying ABIOMED stock?
ABMD stock was purchased by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Franklin Resources Inc., BlackRock Inc., JPMorgan Chase & Co., Rockefeller Capital Management L.P., Prudential Financial Inc., Baillie Gifford & Co. and FIL Ltd. View Insider Buying and Selling for ABIOMED.
How do I buy shares of ABIOMED?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABIOMED's stock price today?
One share of ABMD stock can currently be purchased for approximately $439.11.
How big of a company is ABIOMED?
ABIOMED has a market capitalization of $19.73 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.
How can I contact ABIOMED?
ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for ABIOMED (ABMD)
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
